Isla P. Garraway, MD, PhD

Isla P. Garraway, MD, PhD

Urologic Oncology| Urology
Accepting new patients


Professional Memberships

  • American Urological Association
  • Society of Women in Urology
  • Western Section American Urological Association
  • American Society of Clinical Oncology
  • American Association of Cancer Research
  • Diplomate, American Board of Urology

Academic & Medical Staff Appointments

  • Associate Professor, Department of Urology David Geffen, UCLA School of Medicine, September 2005

Isla P. Garraway received her Bachelor of Science degree from Brown University and completed the Medical Scientist (MD-PhD) Training Program at the David Geffen School of Medicine at UCLA with a doctorate in Molecular Biology. Upon completion of the UCLA Urology residency program, she joined the UCLA faculty. She is currently an Associate Professor of Urology and Director of Research, Member of the Jonsson Comprehensive Cancer Center, and Member of the Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Dr. Garraway is a surgeon-scientist and Principal Investigator of a UCLA basic/translational science laboratory that is focused on characterizing human prostate stem and tumor-initiating cells, as well as biological and microenvironmental interactions that influence metastatic progression. She maintains a clinical practice within the Greater Los Angeles VA Healthcare System, where she also conducts clinical research. Dr. Garraway has received the Donald S. Coffey Career Development, Young Investigator, and Challenge Awards from the Prostate Cancer Foundation. She has also received funding from the National Cancer Institute, the Department of Defense, the Jean Perkins Foundation, the STOP Cancer Foundation, and the Margaret E. Early Foundation.

UCLA Academic Appointments:
Associate Professor, Department of Urology
Director of Research, Department of Urology
Member, Jonsson Comprehensive Cancer Center
Member, Broad Stem Cell Center for Regenerative Medicine and Stem Cell Research

Other Videos




Medical Board Certification

Urology, American Board of Urology, 2009


Urology, UCLA School of Medicine, 2005


Surgery, UCLA School of Medicine, 2000


MD, PhD, UCLA School of Medicine, 1999
PhD, UCLA School of Medicine, 1997


Hospital Affiliations

Ronald Reagan UCLA Medical Center

Areas of Focus


Researcher Minute with Dr. Isla Garraway | UCLA Jonsson Comprehensive Cancer Center



Areas of Research Interest:

  • Prostate stem cells and development
  • Epithelial-mesenchymal interactions in the prostate
  • Functional biomarkers of prostate cancer progression and metastasis
  • Prostate cancer health disparities
  • Prostate cancer biorepositories
  • Multi-omic platform analysis of lethal prostate cancer
  • Digital image analysis applications in prostate cancer
  • Single cell sequencing of prostate tumor populations


  1. Miller, EM, Chamie, K, Kwan, L, Lewis, M, Knudsen, BS, and Garraway, IP*. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. October, 2016, Cancer Medicine, PMID: 27997745; PMCID: PMC5269571.
  2. Brennen, NW, Zhang, B, Kulac, I, Kisteman, N, Antony, L, Wang, H, DeMarzo, AM, Garraway, IP, Denmeade, SR, and Isaacs, JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. July 18, 2017, Oncotarget, PMID 28493842; PMCID: PMCID: 5564518.
  3. Malihi, PD, Morikado, M, Welter, L, Liu, ST, Miller, ET, Cadaneanu, RM, Knudsen, BS, Lewis, MS, Carlsson, A, Velasco, CR, Kolatkar, A, Lee, MR, Garraway, IP, Hicks, J, and Kuhn, P. Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. Converg Sci Phys Oncol 2018;4:015003.PMID: 32670616
  4. Rotinen, M, You, S, Yang, J, Coetzee, S, Huang, W-C, Huang, F, Pan, X, Yanez, A, Hazelett, D, Chu, C-Y, Chung, L, Freedland, S, DiVizio, D, Garraway, I, Murali, R, Knudsen, B, and Freeman, M. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Submitted to Nature Medicine, Nov. 26, 2018. PMID: 30478421
  5. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.PMID: 30935383
  6. Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM. A circulating tumor cell-RNA assay for assessment of androgen receptorsignaling inhibitor sensitivity in metastatic castration-resistant prostate cancer. Theranostics. 2019 Apr 13;9(10):2812-2826. doi: 10.7150/thno.34485. eCollection 2019.PMID: 31244925
  7. Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan T, Huang J, Davicioni E, An SS, Riddle RC, Thorek DLJ, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ. Asporin Restricts Mesenchymal Stromal Cell Differentiation and Drives Metastatic Progression. Cancer Res. 2019 Jul 15;79(14):3636-3650. doi: 10.1158/0008-5472.CAN-18-2931. Epub 2019 May 23. PMID: 31123087
  8. Miller ET, You S, Cadaneanu RM, Kim M, Yoon J, Liu ST, Li X, Kwan L, Hodge J, Quist MJ, Grasso CS, Lewis MS, Knudsen BS, Freeman MR, Garraway IP. Chromosomal instability in untreated prostate cancer as an indicator of metastatic potential. BMC Cancer. 2020 May 7;20(1):398. doi: 10.1186/s12885-020-06817-1.PMID: 32380981
  9. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic heterogeneity of Gleason grade group 5 prostate cancer. Eur Urol. 2020 May 24: S0302-2838(20)30349-3. doi: 10.1016/j.eururo.2020.05.009. Online ahead of print.PMID: 32461072
  10. Lec PM, Lenis AT, Golla V, Brisbane W, Shuch B, Garraway I, Reiter R, Chamie KJ. The role of opoids and their receptors in urologic malignancy: a review. J Urol. 2020 Jun 9:101097JU0000000000001156. doi: 10.1097/JU.0000000000001156. Online ahead of print.PMID: 32516030

Link to Dr. Garraway's PubMed publications


  • Super Doctors® Southern California, 2022, 2023
  • 2018 Los Angeles Magazine Top Doctors
  • Guy Dalla Riva Award 2004
  • American Society of Clinical Investigators Outstanding Research Award 2004
  • Miley B. Wesson Proctor & Gamble Resident Award Winner, Western Section, AUA 2003
  • Los Angeles Urological Resident Award Winner 2003

Recent Grants:

  • UCLA SPORE in Prostate Cancer (co-Investigator)
  • Prostate Cancer Foundation Challenge Award (Principal Investigator)
  • Department of Defense Prostate Cancer Research Program Idea Award (co-Investigator)